TITAN PHARMACEUTICALS
๐ฐ๐ชKenya
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia
Phase 2
Terminated
- Conditions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2005-08-30
- Lead Sponsor
- Titan Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT00083473
- Locations
- ๐บ๐ธ
Center for Lymphoma and Myeloma; Weill Medical College of Cornell University, New York, New York, United States
Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-11-21
- Last Posted Date
- 2005-08-30
- Lead Sponsor
- Titan Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT00073385
- Locations
- ๐ฎ๐ณ
Regional Cancer Centre, Thiruvananthapuram, India
๐บ๐ธHematology and Oncology Specialists, LLC, New Orleans, Louisiana, United States
๐ฌ๐งUniversity of Edinburgh, Edinburgh Cancer Centre, Edinburgh, United Kingdom
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
Phase 1
Terminated
- Conditions
- First Posted Date
- 2002-12-19
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- Titan Pharmaceuticals
- Registration Number
- NCT00050687
- Locations
- ๐บ๐ธ
Highlands Oncology Group, PA, Springdale, Arkansas, United States
๐บ๐ธSouthfield Oncology Institute, Southfield, Michigan, United States
๐บ๐ธCalifornia Cancer Care, Greenbrae, California, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath